company background image

Aileron Therapeutics NasdaqCM:ALRN Stock Report

Last Price


Market Cap







17 Aug, 2022


Company Financials +
ALRN fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health5/6

ALRN Stock Overview

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.

Aileron Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aileron Therapeutics
Historical stock prices
Current Share PriceUS$0.23
52 Week HighUS$1.27
52 Week LowUS$0.13
1 Month Change2.15%
3 Month Change-48.17%
1 Year Change-78.29%
3 Year Change-70.34%
5 Year Change-98.10%
Change since IPO-97.89%

Recent News & Updates

Aug 18
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ALRNUS BiotechsUS Market

Return vs Industry: ALRN underperformed the US Biotechs industry which returned -22.2% over the past year.

Return vs Market: ALRN underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is ALRN's price volatile compared to industry and market?
ALRN volatility
ALRN Average Weekly Movement15.9%
Biotechs Industry Average Movement12.3%
Market Average Movement7.6%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALRN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ALRN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

20019Alves Aivado

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC.

Aileron Therapeutics, Inc. Fundamentals Summary

How do Aileron Therapeutics's earnings and revenue compare to its market cap?
ALRN fundamental statistics
Market CapUS$20.71m
Earnings (TTM)-US$29.92m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALRN income statement (TTM)
Cost of RevenueUS$17.01m
Gross Profit-US$17.01m
Other ExpensesUS$12.91m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ALRN perform over the long term?

See historical performance and comparison